Abstract
“What time should I take my medicine?” is an increasingly important question. Current knowledge of time-of-day effects for specific medications in hospitalized patients with cardiovascular disease is very limited. In such patients, increased medication efficiency could potentially reduce dose use and/or the length of time in the Intensive Care Unit (ICU) and/or hospital – potentially improving patient outcomes and patient and family quality of life, and reducing financial costs. We studied whether the time of day or night a patient is given a diuretic affects urine volume response. In this observational study, data were from 7,704 patients (63% male, 18 to 98 years old) admitted to one hospital’s acute care cardiac units, cardiac ICUs, cardiac surgery ICUs, and/or non-cardiac ICUs, who received intravenous furosemide (a diuretic), had measurements of urine volume, were hospitalized for ≥ 3 days between January 2016 to July 2021 and were older than 18 years. We used machine learning (ML) techniques to analyze the data. The ML technique identified factors that were expected to predict urine volume response to the diuretic: sex, age, medication dose and time, creatinine concentration, diagnosis, and hospital unit. The ML technique also identified medication administration time 00:00–06:00 as a predictor of higher urine volume response. Randomized controlled trials should be conducted to quantify the relative effect of modifiable factors, such as time of medication administration.
Competing Interest Statement
SA, ADA, MDW: none. EBK: Consulting: American Academy of Sleep Medicine Foundation, Circadian Therapeutics, National Sleep Foundation, Sleep Research Society Foundation, Yale University Press. Travel: European Biological Rhythms Society. Other: Partner owns Chronsulting.
Funding Statement
MBW: NIH R01-NS102190, R01-NS102574, R01-NS107291, RF1-AG064312, RF1-NS120947, R01-AG073410, R01-HL161253 and NSF 201443). EBK: NIH R01-NS099055, U01-NS114001, U54-AG062322, R21-DA052861, R21-DA052861, R01-NS114526-02S1, R01-107064; DoD W81XWH201076; and Leducq Foundation for Cardiovascular Research
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The IRB of The Mass General Brigham gave ethical approval for this work
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Support: MBW: NIH R01-NS102190, R01-NS102574, R01-NS107291, RF1-AG064312, RF1-NS120947, R01-AG073410, R01-HL161253 and NSF 201443).
EBK: NIH R01-NS099055, U01-NS114001, U54-AG062322, R21-DA052861, R21-DA052861, R01-NS114526-02S1, R01-107064; DoD W81XWH201076; and Leducq Foundation for Cardiovascular Research
Relevant Conflicts of Interest SA, ADA, MDW: none.
EBK: Consulting: American Academy of Sleep Medicine Foundation, Circadian Therapeutics, National Sleep Foundation, Sleep Research Society Foundation, Yale University Press. Travel: European Biological Rhythms Society. Other: Partner owns Chronsulting.
Data Availability
All data produced in the present study are available upon reasonable request to the authors
